NCT05547321View on ClinicalTrials.gov

Efficacy and Safety Study of OMTX705, Monotherapy and Pembrolizumab-combined, in Subjects With Advanced Solid Tumors.

PHASE1RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

October 20, 2022

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2024

Conditions
Advanced Solid Tumor
Interventions
DRUG

OMTX705

The investigational product is OMTX705 administered as monotherapy.

DRUG

Pembrolizumab

The investigational product is OMTX705 administered in combination with pembrolizumab.

Trial Locations (8)

02215

RECRUITING

Beth Israel Deaconess Medical Center, Boston

Unknown

RECRUITING

ICO L'Hospitalet, L'Hospitalet de Llobregat

RECRUITING

Hospital Universitario de Donostia, San Sebastián

RECRUITING

Clínica Universitaria de Navarra, Pamplona

NOT_YET_RECRUITING

Hospital Universitari Vall d'Hebron, Barcelona

RECRUITING

Hospital 12 Octubre, Madrid

RECRUITING

Hospital MD Anderson, Madrid

RECRUITING

Onkologikoa, San Sebastián

Sponsors
All Listed Sponsors
lead

Oncomatryx Biopharma S.L.

INDUSTRY

NCT05547321 - Efficacy and Safety Study of OMTX705, Monotherapy and Pembrolizumab-combined, in Subjects With Advanced Solid Tumors. | Biotech Hunter | Biotech Hunter